Meeting Banner
Abstract #1124

Monitoring response to drug-loaded PLGA nanoparticles in a Mia PaCa-2 pancreatic tumor model with T2 and diffusion-weighted MRI

Joseph E Kobes 1 , Iman Daryaei 2 , Christine M Howison 1 , Emmaneulle J. Meuillet 3 , and Mark Pagel 4,5

1 Biomedical Engineering, University of Arizona, Tucson, Arizona, United States, 2 Chemistry and Biochemistry, University of Arizona, Tucson, AZ, United States, 3 University of Arizona Cancer Center, University of Arizona, Tucson, Arizona, United States, 4 Dept. of Biomedical Engineering, University of Arizona, Tucson, Arizona, United States, 5 Dept. of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona, United States

Poly(lactic-co-glycolic) acid nanoparticles (PLGA-NP) can improve delivery of PHT-427, a promising AKT-inhibitory chemotherapeutic against pancreatic cancer. To assess the improved therapeutic effect of PLGA-NP-loaded with PHT-427 (PLGA-PH-427), this study employed parametric maps of the Apparent Diffusion Coefficient (ADC) and T2 relaxation time to localized orthotopic pancreatic tumors, and employed ADC measurements to track tumor response to therapy, following treatment of a MiaPaCa-2 pancreatic tumor model with PHT-427 or PLGA-PHT-427.

This abstract and the presentation materials are available to members only; a login is required.

Join Here